)
Edge28 Aug 2026
Bigger, Sharper, IMAX: A Blockbuster Business
How IMAX turned an unscalable, large-screen format into the center of blockbuster filmmaking through cameras, projection, and remastering technology.
Grace Therapeutics
Grace Therapeutics (GRCE) investor relations material
Grace Therapeutics Registration filing summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Registration filing summary24 Aug, 2026
Company overview and business model
Focuses on developing and commercializing products for rare and orphan diseases using novel drug delivery technologies, aiming for enhanced efficacy, faster onset, reduced side effects, and improved patient compliance.
Pipeline includes three clinical-stage drug candidates, all with orphan drug designation, supported by over 79 granted and pending patents globally.
Lead candidate GTx-104 is an injectable nimodipine for IV infusion in aSAH patients, leveraging nanoparticle technology for improved delivery and patient outcomes.
Strategic realignment in 2023 led to a new management team and focus on GTx-104, with internal funding for other candidates paused as of June 2026.
Financial performance and metrics
Private Placement Offering in August 2026 raised approximately $9.1 million in net proceeds from the sale of 4,761,904 shares at $2.10 per share.
Common stock is listed on Nasdaq Capital Market under the symbol "GRCE"; last reported sale price was $2.20 per share on August 21, 2026.
Use of proceeds and capital allocation
Company will not receive any proceeds from the resale of shares by selling stockholders; all proceeds go to the selling stockholders.
Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.Research faster. Power your platform.
Latest events from Grace Therapeutics
- Net loss surged on asset impairment; $19.1M financing extends cash runway through 2028.GRCE
Q1 2027 - GTX-104 IV nimodipine shows superior efficacy, safety, and economic value in aSAH care.GRCECorporate presentation
- Virtual annual meeting to vote on directors, executive pay, and auditor ratification.GRCEProxy filing
- Shareholders will vote on directors, executive pay, auditor ratification, and say-on-pay frequency.GRCEProxy filing
- GTX-104 IV nimodipine shows superior outcomes and economic value in aSAH versus oral therapy.GRCECorporate presentation
- Net loss narrowed as GTx-104 advanced toward FDA resubmission, with strong trial results and IP gains.GRCEQ4 2026
- GTX-104 IV nimodipine outperformed oral therapy in aSAH, improving outcomes and reducing complications.GRCECorporate presentation
- IV nimodipine shows superior efficacy and compliance over oral forms for aSAH treatment.GRCETD Cowen 46th Annual Health Care Conference
- IV nimodipine could transform aSAH care by overcoming oral therapy limitations and improving outcomes.GRCEKOL Event
Next Grace Therapeutics earnings date
Q2 202713 Nov, 2026
Grace Therapeutics
Next Grace Therapeutics earnings date
Q2 202713 Nov, 2026
The essential earnings season companion
The #1 app for qualitative research. Live earnings calls, AI chat, transcripts, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
)
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
)
)
Frequently asked questions
Explore our global coverage